Kraig Biocraft Laboratories says it has shipped its first commercial order of spider silk yarn, made for an unnamed global sports brand. The company did not disclose the volume, the price or the customer, and it reported no revenue in the first half of 2026.
A first commercial order
Kraig Biocraft Laboratories, a Michigan company quoted on the OTCQB under the ticker KBLB, announced on 29 September that it had shipped custom spider silk yarn to fill a purchase commitment from what it called a globally recognised performance sports brand.
The yarn is meant to be developed into a new performance textile. The order is part of a confidential pilot development programme aimed at the innovation end of athletic apparel, and the yarn was processed to the customer's specifications.
Kraig makes its material with genetically engineered silkworms that carry key spider silk proteins, so the worms spin a recombinant spider silk rather than ordinary silk.
Kraig Biocraft Laboratories: share price, chart and news

What the company did and did not say
The release leaves out the numbers investors would normally use to judge an order. There is no quantity, no price and no customer name.
Founder and chief executive Kim Thompson said the volume was small on purpose. "This is a precision application, not a bulk order," she said, adding that the company intends this to be the first of many.
Kraig argued that elite performance apparel is a proving ground for its silk: a successful product would show that recombinant spider silk can meet the technical demands of top-level sport and could draw in other apparel brands. That is the company's view, and it published no test data on the yarn's performance.
The release cited a Textile Exchange report, published on 22 September, showing global fibre production reached a record 139 million tonnes in 2025, with polyester accounting for 59% of the total. Kraig said new fibres must offer different properties and prove they can be made consistently to win a place in that market.
The financial position behind the order
Kraig Labs at 30 June 2026
- $0 revenue in the first six months of 2026
- $1.85m net loss for the six months
- $3.39m cash and cash equivalents
Kraig's most recent quarterly filing with the US Securities and Exchange Commission, for the period to 30 June, shows a company still in development. It had no revenue in the first half and a net loss of $1,852,255, up from $1,326,166 a year earlier.
Cash stood at $3,391,646 at 30 June, up from $1,790,236 at the end of 2025. Most of the increase came from selling shares: in the first half Kraig sold 25,364,093 shares for $2,772,547 under a standby equity purchase agreement that allows it to sell up to $10m of stock to an investor.
The balance sheet is weak. Total liabilities of $11.0m exceeded total assets of $4.3m, leaving a stockholders' deficit of $6.75m, and the company reported a working capital deficiency of $7.33m. Much of the liabilities are amounts owed to a related party. The filing says these conditions raise substantial doubt about Kraig's ability to continue as a going concern.
What it means for investors
A first shipment to a paying customer is a step a development company needs to take. But a small, undisclosed order does not yet show that Kraig can sell spider silk at a scale that covers its costs.
The company had 1,115,334,070 shares outstanding on 13 August. Continued share sales under the equity agreement would add to that count and dilute existing holders, while the going concern warning shows the business depends on raising money.
Investors will be looking for the size and value of any follow-on orders, whether the sports brand turns the yarn into a product, and whether sales start to appear in the company's revenue line.








